Speaker Name: Prof. Melanie J Davies, Professor of Diabetes Medicine, Department of Health Sciences, UK.

Access this session to:

• Understand the role of DPP-4 inhibitors in individualized T2DM management across different ages, comorbidities, and life stages.
• Recognize why early glycemic control and timely treatment intensification are important to reduce therapeutic inertia and future complications.
• Evaluate DPP-4 inhibitors for glucose-lowering efficacy, weight neutrality, low hypoglycemia risk, tolerability, and ease of use.
• Interpret major clinical trial evidence on DPP-4 inhibitors, including cardiovascular safety, heart failure outcomes, and early combination therapy data.
• Strengthen your approach to selecting DPP-4 inhibitors within patient-centered, guideline-based, and combination treatment strategies.